On Monday, Zydus Lifesciences announced that it had received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin Tablets USP, 500 mg.
Zydus Lifesciences announced Monday that it has received final FDA approval to manufacture and market Azithromycin Tablets USP, 500 mg.
According to stock exchanges, the drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad.
In the United States, Azithromycin Tablets USP, 500 mg has an annual sales volume of approximately USD 20 million.